Finally, we propose a paradigm shift: targeting the DHPS/eIF5A axis represents a strategy to disrupt the "non-oncogene addiction" of melanoma-its reliance on hyperactive translation and adaptive survival mechanisms-offering a promising avenue alongside targeted therapies and immunotherapies. Here, EIF5A is linked to melanoma.